Arformoterol Production Cost Reports

The report provides a detailed analysis essential for establishing an arformoterol production plant. It encompasses all critical aspects necessary for arformoterol production, including the cost of arformoterol production, arformoterol plant cost, arformoterol production costs, and the overall arformoterol production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an arformoterol production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Arformoterol is a pharmaceutical compound mainly used in the healthcare industry for the treatment of respiratory disorders. It is primarily used in the treatment of respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is utilised as a long-acting bronchodilator that helps relax the muscles in the airways and improves breathing in patients with chronic obstructive pulmonary disease (COPD). It is prescribed for the maintenance treatment of bronchoconstriction associated with chronic obstructive pulmonary disease (COPD). It finds its main application in inhalation therapies that are administered through nebulisers in hospitals, clinics, and home-care settings. It helps reduce symptoms such as shortness of breath, wheezing, and chest tightness. It is also utilised in combination with other respiratory medications to enhance treatment effectiveness in managing chronic lung conditions. In addition, the compound is often utilised in pharmaceutical research and drug formulation that focuses on developing improved inhalation therapies for respiratory disorders and airway obstruction.

The market for arformoterol is primarily driven by its application as a bronchodilator to prevent bronchoconstriction in people with chronic lung diseases, which boosts its demand in the pharmaceutical industry. Its application as a direct-acting sympathomimetic and bronchodilator for the treatment of chronic obstructive pulmonary disease significantly strengthens its demand in the medical and pharmaceutical industries. Its usage as a medication in inhalation solutions that are administered through nebulisers for long-term maintenance therapy in patients with COPD further promotes its demand in the pharmaceutical and healthcare industries.

Its demand as a maintenance treatment to help manage symptoms such as shortness of breath, wheezing, and chest tightness in patients with long-term lung conditions also supports its market growth. Its usage in combination therapies, where it is used with other respiratory medications to improve treatment effectiveness, also drives its demand in the medical and healthcare sectors. Additionally, industrial arformoterol procurement largely depends on factors, including the cost and availability of pharmaceutical intermediates, regulatory approvals, and strict quality compliance requirements. Moreover, improvements in drug formulation technologies, supplier reliability, sustainability considerations, and well-established distribution networks also influence its procurement strategies across global markets.

Raw Material for Arformoterol Production

According to the arformoterol production plant project report, the major raw materials for arformoterol production include bromoalcohol, formic acid, acetic anhydride, (R)-26 amine salt (with (S)-mandelic acid), and tartaric acid.

Production Process of Arformoterol

The extensive arformoterol production cost report consists of the following industrial production process:

1. Production via Catalytic Reduction: The production process of arformoterol tartrate begins with the preparation of a chiral bromoalcohol intermediate through the catalytic enantioselective reduction of a corresponding bromo ketone. The nitro group present in this intermediate is then reduced by catalytic hydrogenation to form the corresponding aniline. Then, the aniline is quickly treated with a mixture of formic acid and acetic anhydride to prevent oxidation. The concentration of the reaction mixture leads to the formation of a bromohydrin intermediate, which is purified by crystallisation. Then, this bromohydrin is reacted with an amine salt in the presence of a base to generate an epoxide intermediate while releasing the free amine. After aqueous work-up to remove residual salts and mandelic acid, the reaction mixture is heated to allow epoxide ring opening by the amine, which forms the core structure of the target compound. The final step involves the removal of benzyl protecting groups through catalytic hydrogenation, followed by salt formation with tartaric acid to obtain arformoterol tartrate as the final product after crystallisation.

Arformoterol is a selective, long-acting β2-adrenergic receptor agonist and the active (R,R)-(−)-enantiomer of formoterol. It appears as a white to off-white solid powder. The molecular formula of the compound is C19H24N2O4, and its molar mass is 344.41 g/mol. The melting point of the compound is 184 degree Celsius. It has a density of 1.2 g/cm³. The compound exhibits moderate lipophilicity with a LogP of 1.57, and it demonstrates greater water solubility compared to many other β2-agonists, which contributes to its faster onset of action. The compound is also soluble in DMSO and ethanol. It is approximately two-fold more potent than the racemic formoterol and acts as a full or near-full agonist at the β2 receptor. It is commercially available as the tartrate salt under the brand name Brovana and is administered as an inhalation solution. It is advised to follow standard precautions during handling, with storage recommended under cool, dry, and well-ventilated conditions away from light.